Autopsy report · NCT00899678

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

Cause of deathSlow enrollment Automatic label, confidence 0.5, unverified. How labels are made.

“higher than projected discontinuation rate during Maintenance Phase”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 3 years 3 months before it stopped.
99 participants enrolled.
Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: UCB Celltech
Sponsor type: Industry
Conditions: Crohn's Disease
Interventions: Certolizumab Pegol; Certolizumab Pegol
Participants: 99
Sites: 35
Countries: Australia, Canada, New Zealand, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.